Floatz logo

5-((R)-SEC-BUTYLAMINO)-N1-((1R,3S,5S)-8-(5-(CYCLOPROPANECARBONYL)PYRIDIN-2-YL)-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-2-METHYLTEREPHTHALAMIDE

Colorectal Adenocarcinoma

Emory UniversitySmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

67 Active assets in the Colorectal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Trifluridine
Centre Hospitalier Universitaire Dijon
Phase 3BB
Regorafenib
City of Hope Medical Center
Phase 2BB
Balstilimab
City of Hope Medical Center
Phase 2BB
Botensilimab
City of Hope Medical Center
Phase 2BB
Cetuximab
Bayer
Phase 2BB

View all 50 →

Same molecule, other indications

5-((R)-SEC-BUTYLAMINO)-N1-((1R,3S,5S)-8-(5-(CYCLOPROPANECARBONYL)PYRIDIN-2-YL)-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-2-METHYLTEREPHTHALAMIDE is also rated in:

colorectal carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
exocrine pancreatic carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →